GS-US-563-5926: Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care

CONDITION

Other

GENDER

All

AGE GROUP

From 18

and above

STATUS

Active, not recruiting

A Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate a Switch to an Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care

Studies Contact Form

Approved By: Bellberry limited              

Clinical Trial Registry Link:


Notice: Function WP_Scripts::add was called incorrectly. The script with the handle "gforms_recaptcha_frontend" was enqueued with dependencies that are not registered: gforms_recaptcha_recaptcha. Please see Debugging in WordPress for more information. (This message was added in version 6.9.1.) in /srv/users/australianclinicaltrials/apps/australianclinicaltrials/public/wp-includes/functions.php on line 6260